Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR) - α and γ agonist against a rat model of oral dyskinesia

Pharmacology Biochemistry and Behavior

Volumn 111, Issue , 2013, Pages 17-23

  Grover, Sania ^a   Kumar, Puneet ^a   Singh, Kuldeep ^a   Vikram, Vir ^a   Budhiraja, R D ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Choriform; Fenofibrate; Haloperidol; Oral dyskinesia; Pioglitazone; Vacuous chewing movements

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; FENOFIBRATE; HALOPERIDOL; INTERLEUKIN 1BETA; NEUROPROTECTIVE AGENT; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; GROOMING; MALE; MASTICATION; MAZE TEST; MEMORY CONSOLIDATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT;

ANIMALIA; RATTUS;

CHORIFORM; FENOFIBRATE; HALOPERIDOL; ORAL DYSKINESIA; PIOGLITAZONE; VACUOUS CHEWING MOVEMENTS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; FENOFIBRATE; HALOPERIDOL; L-LACTATE DEHYDROGENASE; MALE; MOUTH; MOVEMENT DISORDERS; OXIDATIVE STRESS; PPAR ALPHA; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84883083534     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.08.001     Document Type: Article

References (52)

1. P.G. Aia, and G.J. Revuelta Tardive dyskinesia Curr Treat Options Neurol 13 2011 231 241
2. V.C. Besson, X.R. Chen, M. Plotkine, and C. Marchand-Verrecchia Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury Neurosci Lett 388 2005 7 12 (Pubitemid 41569361)
3. D.K. Bhateja, D.K. Dhull, A. Gill, A. Sidhu, S. Sharma, and B.V. Reddy Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms Eur J Pharmacol 674 2012 33 43
4. M. Bishnoi, K. Chopra, and S.K. Kulkarni Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia Pharmacol Rep 59 2007 181 191 (Pubitemid 46952408)
5. M. Bishnoi, K. Chopra, and S.K. Kulkarni Activation of striatal inflammatory mediators and caspase-3 is central to haloperidol-induced orofacial dyskinesia Eur J Pharmacol 590 2008 241 245
6. M. Bishnoi, K. Chopra, and S.K. Kulkarni Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain Pharmacol Biochem Behav 88 2008 511 522 (Pubitemid 350266795)
7. M. Bishnoi, K. Chopra, and S.K. Kulkarni Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels Pharmacol Biochem Behav 91 2009 423 429
8. R. Bordet, T. Ouk, O. Petrault, P. Gelé, S. Gautier, and M. Laprais PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases Biochem Soc Trans 34 2006 1341 1346 (Pubitemid 46769051)
9. M.B.E. Burger, R. Fachineto, A. Alves, L. Callegari, and J.B.T. Rocha Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain Pharmacol Biochem Behav 81 2005 608 615 (Pubitemid 40966809)
10. J.L. Cadet, and J.B. Lohr Possible involvement of free radicals in neuroleptic-induced movement disorders evidence from treatment of tardive dyskinesia with vitamin E. Annals of the New York Academy of Sciences Vitamin E: biochemistry and health implications Ann N Y Acad Sci 570 1989 176 185 (Pubitemid 20103394)
11. C.B. Carroll, M.L. Zeissler, C.O. Hanemann, and J.P. Zajicek Δ(9)-THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease Neuropathol Appl Neurobiol 38 2012 535 547
12. R. Dawson, M.F. Beal, S.C. Bondy, D. Monte, and G.E. Isom Excitotoxins, aging and environmental neurotoxins: implications for understanding human neurodegenerative diseases Toxicol Appl Pharmacol 134 1995 1 17
13. V. Dhikav, and K.S. Anand Potential predictors of hippocampal atrophy in Alzheimer's disease Drugs Aging 28 2011 1 11
14. G. Ellison, P. Johansson, E. Levin, R. See, and L. Gunne Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats Psychopharmacology 96 2 1988 253 257
15. G.L. Ellman Tissue sulfhydryl groups Arch Biochem Biophys 82 1959 70 77
16. G. Gornall, C. Bardawill, and M. David Determination of serum proteins by means of the Biuret reaction J Biol Chem 177 1949 751 766
17. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannebaum Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids Ann Biochem 126 1982 131 138 (Pubitemid 13203451)
18. M.T. Heneka, and G.E. Landreth PPARs in the brain Biochim Biophys Acta 1771 2007 1031 1045 (Pubitemid 47208548)
19. K. Ishiwari, A. Betz, S. Weber, J. Felsted, and J.D. Salamone Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics effects of pimozide (Orap) in rats Pharmacol Biochem Behav 80 2005 351 362 (Pubitemid 40170431)
20. H. Kalonia, P. Kumar, and A. Kumar Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-IΥ (PPAR-IΥ) in Huntington's disease Pharmacol Biochem Behav 96 2010 115 124
21. M. Kiaei Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease PPAR Res 2008 2008 418765
22. L. Krabbendam, P.N. van Harten, I. Picus, and J. Jolles Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curaçao Extrapyramidal Syndromes Study: IV Schizophr Res 42 2000 41 46 (Pubitemid 30118743)
23. A. Kreisler, A. Duhamel, C. Vanbesien-Mailliot, A. Destée, and R. Bordet Differing short term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease Behav Pharmacol 21 2010 194-05
24. S.K. Kulkarni, and A. Dhir Animal models of tardive dyskinesia Int Rev Neurobiol 98 2011 265 287
25. S.K. Kulkarni, and P.S. Naidu Pathophysiology and drug therapy of tardive dyskinesia current concepts and future perspectives Drugs Today (Barc) 39 2003 19 49 (Pubitemid 36378460)
26. S.K. Kulkarni, M. Bishnoi, and K. Chopra In VIVO microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration Indian J Exp Biol 47 2009 91 97
27. P. Kumar, and A. Kumar Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats Pharmacol Rep 60 2008 706 715
28. P. Kumar, and A. Kumar Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism Food Chem Toxicol 47 2009 2522 2530
29. P. Kumar, H. Kalonia, and A. Kumar Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: a comparative study J Psychopharmacol 10 2011 1399 1411
30. P. Kumar, H. Kalonia, and A. Kumar Role of LOX/COX pathways in 3-nitropropionic acid induced Huntington's Disease-like symptoms in rats: protective effect of licofelone Br J Pharmacol 164 2011 644 654
31. P. Latha, A.S. Kumar, S.M. Lakshmi, V.H. Chowdary, D. Nagarjuna, and N.U. Sri OCIMUM SANCTUM Linn attenuates haloperidol induced tardive dyskinesia and associated behavioral, biochemical and neurochemical changes in rats Int J Phytopharmacology 1 2010 74-1
32. Q. Lei, A. Jacob, P. Wang, and R. Wu Peroxisome proliferator activated receptor-γ and traumatic brain injury Int J Clin Exp Med 3 2010 283 292
33. H. Luck Catalase spectrophotometric method H.U. Bergmeyer, Methods in Enzymatic Analysis 1963 Academic Press New York 885 893
34. B. Medhi, R. Aggarwal, and A. Chakrabarti Neuroprotective effect of pioglitazone on acute phase changes induced by partial global cerebral ischaemia in mice Indian J Exp Biol 48 2010 793 799
35. L.A. Moraes, L. Piqueras, and D. Bishop-Bailey Peroxisome proliferator-activated receptors and inflammation Pharmacol Ther 110 2006 371 385
36. K. Murakami, K. Tobe, T. Ide, T. Mochizuki, M. Ohashi, and Y. Akanuma A novel insulin sensitizer acts as a co-ligand for peroxisome proliferator activated receptor-α (PPAR-α) and PPAR-IΥ effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats Diabetes 47 1998 1841 1847 (Pubitemid 28549189)
37. P.S. Naidu, and S.K. Kulkarni Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats Eur J Pharmacol 430 2001 295 298 (Pubitemid 33050053)
38. P.S. Naidu, A. Singh, and S.K. Kulkarni Quercetin a bioflavonoid attenuated haloperidol induced orofacial dyskinesia Neuropharmacology 44 2003 1100 1106
39. A.C.P. Oliveira, C.M. Bertollo, L.T.S. Rocha, E.B. Nascimento, K.A. Costa, and M.M. Coelho Anti-nociceptive anti-edematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma Eur J Pharmacol 561 2007 194-01 (Pubitemid 46435842)
40. A.R. Pathan, B. Viswanad, S.K. Sonkusare, and P. Ramarao Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats Life Sci 79 2006 2209 2216 (Pubitemid 44646475)
41. G.E. Ploeger, B.M. Spruijt, and A.R. Cools Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol Behav Neurosci 108 1994 927 934 (Pubitemid 24322263)
42. M.K. Racke, and P.D. Drew PPARs in neuroinflammation PPAR Res 2008 2008 638356
43. H. Rosengarten, and D. Quatermain The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three and eighteen month old rats Prog Neuropsychopharmacol Biol Psychiatry 26 2002 1047 1054 (Pubitemid 35256096)
44. N. Samad, M.A. Haleem, and D.J. Haleem Behavioral effects of 1-(m-chlorophenyl) piperazine (m-CPP) in a rat model of tardive dyskinesia Pak J Pharm Sci 21 2008 262 268
45. M.J. Santos, R.A. Quintanilla, A. Toro, R. Grandy, M.C. Dinamarca, and J. Godoy Peroxisomal proliferation protects from beta-amyloid neurodegeneration J Biol Chem 280 2005 41057 41068 (Pubitemid 41780601)
46. P. Seeman, T. Lee, M. Chau-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717 719
47. C.S. Swanson, V. Joers, V. Bondarenko, K. Brunner, H.A. Simmons, and T.E. Ziegler The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys J Neuroinflammation 8 2011 91
48. S. Thaakur, and G. Himabindhu Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats J Neural Transm 116 2009 807 814
49. G.K. Thaker, A.J. Nguyen, and C.A. Tamminga Increased saccadic distractibility in tardive dyskinesia: functional evidence for subcortical GABA dysfunction Biol Psychiatry 1 1988 49 59 (Pubitemid 19030223)
50. S.C. Thal, M. Heinemann, C. Luh, D. Pieter, C. Werner, and K. Engelhard Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms J Neurotrauma 28 2011 983 993
51. E.D. Wills Mechanism of lipid peroxide formation in animal tissues Biochem J 99 1965 667 676
52. G.Q. Xiang, S.S. Tang, L.Y. Jiang, Q. Hong Li, C. Wang, and X.Y. Wang PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice J Pharm Pharmacol 64 2012 589 596